Xenon Pharmaceuticals Inc Developing Novel Non-Opioid Treatments for Pain – An Overview of Xenon’s Nav1.7 and Kv7 Programs. Transcript - Thomson StreetEvents

Xenon Pharmaceuticals Inc Developing Novel Non-Opioid Treatments for Pain – An Overview of Xenon’s Nav1.7 and Kv7 Programs. Transcript

Xenon Pharmaceuticals Inc Developing Novel Non-Opioid Treatments for Pain – An Overview of Xenon’s Nav1.7 and Kv7 Programs. Transcript - Thomson StreetEvents
Xenon Pharmaceuticals Inc Developing Novel Non-Opioid Treatments for Pain – An Overview of Xenon’s Nav1.7 and Kv7 Programs. Transcript
Published Oct 06, 2025
15 pages (10652 words) — Published Oct 06, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of XENE.OQ corporate analyst meeting

  
Brief Excerpt:

...Good morning, everyone. My name is Ian Mortimer, I'm the President and CEO of Xenon Pharmaceuticals, and I will be moderating today's session. Thank you for joining us on this investor webinar focused on our Kv7 and Nav1.7 programs in the development for the treatment of pain. Before diving into the speaker introductions and agenda for today, please note the standard notice that we will make a number of statements that are forward-looking. I encourage you to review our SEC filings for a more fulsome discussion of risks facing our business, and readers are cautioned not to place undue reliance on such forward-looking statements. With that, I'm pleased to introduce my colleagues who are speaking on today's call: Dr. Jim Empfield, Xenon's Executive Vice President, Drug Discovery; Dr. JP Gilbert, Xenon's Senior Director of Biology; and Dr. Chris Kenney, Xenon's Chief Medical Officer. To kick us off, I'll provide a brief corporate overview, including our current pipeline. Jim will then provide...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Xenon Pharmaceuticals Inc
Ticker
XENE.OQ
Time
3:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Xenon Pharmaceuticals Inc Azetukalner and Epilepsy Data Update Call Transcript – 2025-12-10 – US$ 54.00 – Edited Transcript of XENE.OQ conference call or presentation 10-Dec-25 3:00pm GMT

Xenon Pharmaceuticals Inc Q3 2025 Earnings Call Transcript – 2025-11-03 – US$ 54.00 – Edited Transcript of XENE.OQ earnings conference call or presentation 3-Nov-25 9:30pm GMT

Xenon Pharmaceuticals Inc Q2 2025 Earnings Call Transcript – 2025-08-11 – US$ 54.00 – Edited Transcript of XENE.OQ earnings conference call or presentation 11-Aug-25 8:30pm GMT

Xenon Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript – 2025-06-10 – US$ 54.00 – Edited Transcript of XENE.OQ presentation 10-Jun-25 7:20pm GMT

Xenon Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript – 2025-05-21 – US$ 54.00 – Edited Transcript of XENE.OQ presentation 21-May-25 2:30pm GMT

Xenon Pharmaceuticals Inc Q1 2025 Earnings Call Transcript – 2025-05-12 – US$ 54.00 – Edited Transcript of XENE.OQ earnings conference call or presentation 12-May-25 8:30pm GMT

Xenon Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript – 2025-03-04 – US$ 54.00 – Edited Transcript of XENE.OQ presentation 4-Mar-25 3:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Xenon Pharmaceuticals Inc Developing Novel Non-Opioid Treatments for Pain – An Overview of Xenon’s Nav1.7 and Kv7 Programs. Transcript" Oct 06, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Xenon-Pharmaceuticals-Inc-Developing-Novel-Non-Opioid-Treatments-for-Pain-An-Overview-of-Xenon-s-Nav1-7-and-Kv7-Programs-T16516648>
  
APA:
Thomson StreetEvents. (2025). Xenon Pharmaceuticals Inc Developing Novel Non-Opioid Treatments for Pain – An Overview of Xenon’s Nav1.7 and Kv7 Programs. Transcript Oct 06, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Xenon-Pharmaceuticals-Inc-Developing-Novel-Non-Opioid-Treatments-for-Pain-An-Overview-of-Xenon-s-Nav1-7-and-Kv7-Programs-T16516648>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.